Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,...
Reexamination Certificate
2011-08-30
2011-08-30
Salimi, Ali R. (Department: 1649)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
C424S133100, C424S134100, C424S135100, C424S136100, C424S139100, C424S141100, C424S142100, C424S145100, C435S975000
Reexamination Certificate
active
08007791
ABSTRACT:
The invention concerns the prevention and treatment of complement-associated eye conditions, such as choroidal neovascularization (CNV) and age-related macular degeneration (AMD), by administration of Factor D antagonists.
REFERENCES:
patent: 6410708 (2002-06-01), Ashkenazi et al.
patent: 6472520 (2002-10-01), Fisher
patent: 6569992 (2003-05-01), LaFleur et al.
patent: 6642353 (2003-11-01), McConnell et al.
patent: 6838554 (2005-01-01), Ashkenazi et al.
patent: 7192589 (2007-03-01), Ashkenazi et al.
patent: 7211400 (2007-05-01), Ashkenazi et al.
patent: 7282565 (2007-10-01), Goddard et al.
patent: 7419663 (2008-09-01), Ashkenazi et al.
patent: 2004/0152105 (2004-08-01), Vogt et al.
patent: 2005/0197285 (2005-09-01), Rosen et al.
patent: 2006/0233803 (2006-10-01), Ashkenazi et al.
patent: 2007/0190054 (2007-08-01), Ashkenazi et al.
patent: 2009/0214538 (2009-08-01), Fung et al.
patent: WO 99/27098 (1999-03-01), None
patent: WO 99/40100 (1999-08-01), None
patent: WO 99/42133 (1999-08-01), None
patent: WO 99/46281 (1999-09-01), None
patent: WO 00/12703 (2000-03-01), None
patent: WO 00/37638 (2000-06-01), None
patent: WO 00/53749 (2000-09-01), None
patent: WO 00/53758 (2000-09-01), None
patent: WO 01/04311 (2001-01-01), None
patent: WO 01/36432 (2001-05-01), None
patent: WO 01/36102 (2001-06-01), None
patent: WO 01/40466 (2001-06-01), None
patent: WO 02/00690 (2002-01-01), None
patent: WO 02/08284 (2002-01-01), None
patent: WO 2004/022594 (2004-03-01), None
patent: WO 2006/042329 (2006-04-01), None
patent: WO 2006/071856 (2006-07-01), None
patent: WO 2007/056227 (2007-05-01), None
patent: WO 2007/087384 (2007-08-01), None
patent: WO 2009/011461 (2009-09-01), None
Bora, P., et al., The Journal of Immunology, 174(1): 491-497 (2005).
Harboe, M., et al., Clinical and Experimental Immunology, 138(3): 439-446 (2004).
Petrukhin, K., et al., Expert Opinion on Therapeutic Targets, 11(5): 625-639 (2007).
Tanhehco, E., et al., Transplantation Proceedings, 31(5): 2168-2171 (1999).
Akif, U., et al., The Annals of Thoracic Surgery, 74(2): 355-362 (2002).
Aderem, et al., “Mechanisms of phagocytosis in macrophages”, Annu. Rev. Immnuol., 17: 593-623, (1999).
Arrate, et al., “Cloning of human junctional adhesion molecule 3 (JAM3) and its identification as the JAM2 counter-receptor”, The journal of biological chemistry, vol. 276, No. 49, pp. 45826-45832, (2001).
Attwood, “The Babel of Bioinformatics”, Science 290: 471-473, (2000).
Brown, “Complement receptors, adhesion and phagocytosis”, Infectious agents and disease, 1:63-70, (1992).
Carroll, “The complement system in regulation of adaptive immunity”, Nature Immunology, vol. 5, No. 10, pp. 981-986, (2004).
Casset, et al., “A peptide mimetic of an anti-CD4 monoclonal antibody by rational design”, BBRC, (2003) 307: 198-205, (2003).
Database Genebank (Apr. 24, 2001), “Human Pro 1868 Protein” Database Accession No. AAB80272, XP002448361.
Edwards, et al., “Complement factor H polymorphism and age-related macular degeneration”, Science, vol. 308, pp. 421-424, (2005).
Haines, et al., “Complement factor H variant increases the risk of age-related macular degeneration”, Science, vol. 308, pp. 419-421, (2005).
Holers, et al., “The evolution of mouse and human complement C3-binding proteins. divergence of form but conservation of function”, Immunology Today, vol. 13, No. 6, pp. 231-236, (1992).
Janssen, et al., “Structural insights into the central complement component C3”, Molecular Immunology, 44:3-10, (2007).
Katschke, et al., “A novel inhibitor of the alternative pathway of complement reverses inflammation and bone destruction in experimental arthritis”, Brief Definitive Report, vol. 204, No. 6, pp. 1319-1325, (2007).
Kim, et al., “Characterization of monoclonal antibody specific to the Z391g protein, a member of immunoglobulin superfamily”, Immunology Letters, 99: 153-161, (2005).
Klein, et al., “Complement factor H polymorphism in age-related macular degeneration”, Science, vol. 308, pp. 385-389, (2005).
Langnaese, et al., “Cloning of Z391g, a novel gene with immunoglobulin-like domains located on human chromosome X1”, BBA, pp. 522-525, (2000).
Lee, et al., “Z391g is expressed on macrophages and may mediate inflammatory reactions in arthritis and atherosclerosis”, Journal of Leukocyte biology, vol. 80, pp. 922-928, (2006).
MacCallum, et al., “Antibody-antigen interactions: Contact analysis and binding site topography”, J. Mol. Biol., 262:,'732-745, (1996).
Pyz, et al., “C-type lectin-like receptors on myeloid cells”, Annals of Medicine, 38: 242-251, (2006).
Ross, et al., “Membrane complement receptors specific for bound fragments of C3”, Advances in Immunology, vol. 37, pp. 217-267, (1985).
Rudikoff, et al., “Single amino acid substitution altering antigen-binding specificity”, PNAS, vol. 79, pp. 1979-1983, (1982).
Skolnick, et al., “From genes to protein structure and function: novel applications of computational approaches in the genomic era”, Trends in Biotech.,18:34-39, (2000).
Strausberg, et al., “Generation and initial analysis of more than 15,000 full-length human and mouse cDNA se uences”, PNAS, vol. 99, No. 26 es 16899-16903, (2002).
Stuart, et al., “Phagocytosis: Elegant complexity”, Immunity, vol. 22, pp. 539-550, (2005).
Taylor, et al., “Macrophage receptors and immune recognition”, Annu. Rev. Immunol., 23: 901-944, (2005).
Taylor, et al., “Pattern recognition receptors and differentiation antigens define murine myeloid cell heterogeneity ex vivo”, Eur. J. Immunol., 33: 2090-2097, (2003).
Thurman, et al., “The central role of the alternative complement pathway in human disease”, The Journal of Immunology, 176: 1305-1310, (2006).
Tsukita, et al., “Multifunctional strands in tight junctions”, Nature Reviews, vol. 2, pp. 285-293, (2001).
Underhill, et al., Phagocytosis of microbes: Complexity in action, Annu. Rev. Immunol., 20: 825-852, (2002).
Walker, et al., Z391g is co-expressed with activation macrophage genes' Biochimica et Biophysica Acta, 1574: 387-390, (2002).
Walport, “Complement: first of two parts”, Advances in Immunology, N. Eng. J. Med., vol. 344, No. 14, pp. 1058-1066, (2001).
Wu, et al., “Humanization of a murine monoclonal antibody by simultaneous optimization of framework and CRD residues”, JMB, 294: 151-162, (1999).
Campagne Menno Van Lookeren
Hass Philip
Jianping Yin
Katschke, Jr. Kenneth
Steffek Micah
Arnold & Porter LLP
Dreger Ginger R.
Genentech Inc.
Gucker Stephen
Salimi Ali R.
LandOfFree
Prevention and treatment of complement-associated eye... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Prevention and treatment of complement-associated eye..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Prevention and treatment of complement-associated eye... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2711703